{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:24:04Z","timestamp":1791869044820,"version":"4.3.4"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.0819","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T20:58:11Z","timestamp":1555102691000},"page":"e190819","source":"Crossref","is-referenced-by-count":30,"title":["Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA)"],"prefix":"10.1001","volume":"2","author":[{"given":"Helen C.","family":"Stankiewicz Karita","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Hauge","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Magaret","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Washington, Seattle"},{"name":"Division of Vaccine and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Department of Laboratory Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schouten","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"Division of Vaccine and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Department of Surgery, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Grieco","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long Fu","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise A.","family":"Galloway","sequence":"additional","affiliation":[{"name":"Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Madeleine","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle"},{"name":"Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wald","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"Division of Vaccine and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Department of Laboratory Medicine, University of Washington, Seattle"},{"name":"Department of Epidemiology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"issue":"4","key":"zoi190049r1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.v141.4","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type.","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"issue":"6","key":"zoi190049r2","doi-asserted-by":"publisher","first-page":"djv086","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.","volume":"107","author":"Saraiya","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"zoi190049r3","doi-asserted-by":"publisher","first-page":"918","DOI":"10.15585\/mmwr.mm6733a2","article-title":"Trends in human papillomavirus-associated cancers\u2014United States, 1999-2015.","volume":"67","author":"Van Dyne","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"zoi190049r5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1309\/AJCPTGD94EVRSJCG","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.","volume":"137","author":"Saslow","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"zoi190049r7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1097\/01.AOG.0000187301.76283.7f","article-title":"Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women.","volume":"106","author":"Jones","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"2","key":"zoi190049r8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ygyno.2005.02.012","article-title":"Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? a systematic review of 3322 published patients.","volume":"97","author":"van Seters","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"5","key":"zoi190049r9","doi-asserted-by":"publisher","first-page":"F24","DOI":"10.1016\/j.vaccine.2012.05.089","article-title":"Updating the natural history of human papillomavirus and anogenital cancers.","volume":"30","author":"Moscicki","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"zoi190049r11","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1097\/AOG.0000000000001713","article-title":"Committee opinion No. 675: management of vulvar intraepithelial neoplasia.","volume":"128","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Gynecologic Practice","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"6","key":"zoi190049r12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/jdv.2017.31.issue-6","article-title":"2016 European guideline for the management of vulval conditions.","volume":"31","author":"van der Meijden","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"zoi190049r13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1470-2045(13)70067-6","article-title":"Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial.","volume":"14","author":"Richel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi190049r14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ygyno.2017.10.029","article-title":"Vulvar intraepithelial neoplasia: risk factors for recurrence.","volume":"148","author":"Satmary","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"3","key":"zoi190049r15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3802\/jgo.2013.24.3.236","article-title":"Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia.","volume":"24","author":"Fehr","year":"2013","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"zoi190049r16","first-page":"393","article-title":"Vulval intraepithelial neoplasia: current perspectives.","volume":"22","author":"Jones","year":"2001","journal-title":"Eur J Gynaecol Oncol"},{"issue":"6","key":"zoi190049r17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10350-008-9233-4","article-title":"High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience.","volume":"51","author":"Pineda","year":"2008","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"zoi190049r18","first-page":"962","article-title":"Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence.","volume":"92","author":"Modesitt","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"2","key":"zoi190049r19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ygyno.2012.07.118","article-title":"Vulvar intraepithelial neoplasia (VIN 2\/3): comparing clinical outcomes and evaluating risk factors for recurrence.","volume":"127","author":"Wallbillich","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"10","key":"zoi190049r20","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/DCR.0b013e318227833e","article-title":"Long-term follow-up of infrared coagulator ablation of anal high-grade dysplasia in men who have sex with men.","volume":"54","author":"Goldstone","year":"2011","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"zoi190049r21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/LGT.0000000000000227","article-title":"Natural antibodies to human papillomavirus 16 and recurrence of vulvar high-grade intraepithelial neoplasia (VIN3).","volume":"20","author":"Madeleine","year":"2016","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"zoi190049r22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines\u2014a review of the first decade.","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"8","key":"zoi190049r23","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1086\/653020","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men.","volume":"202","author":"Wilkin","year":"2010","journal-title":"J Infect Dis"},{"issue":"1","key":"zoi190049r24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/cid\/ciu238","article-title":"Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.","volume":"59","author":"Kojic","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"zoi190049r25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.vaccine.2008.10.088","article-title":"Immunogenicity and tolerability of an HPV-16\/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"zoi190049r26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"issue":"12","key":"zoi190049r27","doi-asserted-by":"publisher","first-page":"e83431","DOI":"10.1371\/journal.pone.0083431","article-title":"Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil\u2122 in adult women.","volume":"8","author":"Luna","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"zoi190049r28","doi-asserted-by":"publisher","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"issue":"2","key":"zoi190049r29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"7","key":"zoi190049r30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/cid\/cir1036","article-title":"Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study.","volume":"54","author":"Swedish","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"10","key":"zoi190049r31","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccin"},{"key":"zoi190049r32","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus.","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"zoi190049r33","doi-asserted-by":"publisher","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines\u2014immune responses.","volume":"30","author":"Stanley","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"zoi190049r34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/jid.2003.188.issue-2","article-title":"Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.","volume":"188","author":"Pinto","year":"2003","journal-title":"J Infect Dis"},{"issue":"4","key":"zoi190049r35","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/21645515.2017.1407896","article-title":"Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.","volume":"14","author":"Zurek Munk-Madsen","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"zoi190049r36","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/infdis\/jis489","article-title":"Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children.","volume":"206","author":"Weinberg","year":"2012","journal-title":"J Infect Dis"},{"issue":"24","key":"zoi190049r37","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Dynamic balanced randomization for clinical trials.","volume":"12","author":"Signorini","year":"1993","journal-title":"Stat Med"},{"issue":"3","key":"zoi190049r38","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2307\/2532360","article-title":"Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model.","volume":"48","author":"Odell","year":"1992","journal-title":"Biometrics"},{"issue":"1","key":"zoi190049r39","doi-asserted-by":"publisher","first-page":"e0116774","DOI":"10.1371\/journal.pone.0116774","article-title":"Statistical inference methods for two crossing survival curves: a comparison of methods.","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"zoi190049r40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Comparing two crossing hazard rates by Cox proportional hazards modelling.","volume":"26","author":"Liu","year":"2007","journal-title":"Stat Med"},{"issue":"1","key":"zoi190049r41","first-page":"19","article-title":"Validity and power of tests when groups have been balanced for prognostic factors.","volume":"5","author":"Forsythe","year":"1987","journal-title":"Comput Stat Data Anal"},{"issue":"6","key":"zoi190049r42","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0197-2456(02)00242-8","article-title":"The method of minimization for allocation to clinical trials. a review.","volume":"23","author":"Scott","year":"2002","journal-title":"Control Clin Trials"},{"issue":"9","key":"zoi190049r43","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/cid\/ciy274","article-title":"A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS Clinical Trials Group Protocol A5298.","volume":"67","author":"Wilkin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"zoi190049r44","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1111\/ajt.12472","article-title":"HPV-related cancers after solid organ transplantation in the United States.","volume":"13","author":"Madeleine","year":"2013","journal-title":"Am J Transplant"},{"issue":"9581","key":"zoi190049r45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"zoi190049r46","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis.","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi190049r47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7326\/M16-2094","article-title":"Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study.","volume":"169","author":"Park","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi190049r48","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/bjo.1996.103.issue-5","article-title":"Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women.","volume":"103","author":"Herod","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"key":"zoi190049r4","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts. https:\/\/seer.cancer.gov\/statfacts\/. Accessed February 27, 2018."},{"key":"#cr-split#-zoi190049r6.1","unstructured":"2. NooneAM, HowladerN, KrapchoM, eds. SEER Cancer Statistics Review, 1975-2015. Bethesda, MD: National Cancer Institute"},{"key":"#cr-split#-zoi190049r6.2","doi-asserted-by":"crossref","unstructured":"10.1097\/JOM.0000000000000152","DOI":"10.1097\/JOM.0000000000000152"},{"key":"zoi190049r10","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER database. http:\/\/www.seer.cancer.gov. Published April 2018. Accessed August 2018."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/4\/e190819\/17465261\/stankiewicz_karita_2019_oi_190049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T20:58:26Z","timestamp":1555102706000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2019.0819"}},"subtitle":["A Trial Protocol"],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0819","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]}}}